Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial
Executive Committee, National Coordinators, Consulting Statistician, Clinical Events Committee, Scientific Excellence Committee, Data Monitoring Committee, the EMPEROR-Reduced Trial Committees and Investigators
Dive into the research topics of 'Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial'. Together they form a unique fingerprint.